A new study involving OCEANIUM’s seaweed-derived prebiotic, OCEAN ACTIVES H+, has demonstrated the product’s ability to enhance gut health.
Published in Microorganisms, the 12-week, double-blind, clinical study found that the nutraceutical can not only promote gut microbiome balance, but also amplify genetic pathways linked to inflammation reduction, metabolic function and short-chain fatty acid (SCFA) production.1
During the trial, the benefits of two daily doses (250mg and 1g) of the fucoidan extract were tested against a placebo, with the low-dose cohort experiencing similar benefits without gastrointestinal (GI) discomfort.
"OCEAN ACTIVES H+'s efficacy at a dose of 250mg is significant, as the gut health market is inundated with high-dose prebiotics that often cause GI discomfort," notes Oceanium's Sales Director for Nutraceuticals, Patrick Bomont.
"By offering a solution that is both low-dose and truly effective, we can help supplement manufacturers create consumer-friendly products that encourage continued supplement adherence," he adds.
To delve deeper into the science behind OCEAN ACTIVES H+ and the future of marine-derived prebiotics, NBR sat down with Bomont.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.
